文献速递脑血管病

基底动脉闭塞患者转院前静脉溶栓对取栓的有效性与安全性

Effectiveness and Safety of IV Thrombolysis Before Hospital Transfer for Thrombectomy in Patients With Basilar Artery Occlusion.
PubMed 文献 · Neurology · 2025-11-19

本研究分析3个前瞻性队列中230例从初级卒中中心转至综合卒中中心考虑取栓的基底动脉闭塞患者,39%在转院前接受静脉溶栓。调整混杂因素后,转院前静脉溶栓与3个月良好功能结局独立相关(39% vs 24%,aOR 2.02,95%CI 1.03-3.97,p=0.04),并与转院期间基底动脉再通相关(aOR 23.7,95%CI 6.9-81.3,p<0.001),而90天死亡率和24小时任何脑出血无显著差异。

要点

  • 转院前静脉溶栓与基底动脉闭塞患者3个月良好功能结局独立相关。
  • 转院前静脉溶栓显著增加转院期间基底动脉再通,未增加死亡或脑出血风险。
  • 仅39%患者接受静脉溶栓,提示该场景下溶栓标准可能需要放宽。

核心结论

  • 在因取栓考虑而转院的基底动脉闭塞患者中,转院前静脉溶栓与再通改善和功能结局改善相关,且无显著安全性担忧。

研究设计与样本

  • 研究分析了3个前瞻性收集的队列,纳入从初级卒中中心转至综合卒中中心考虑取栓的基底动脉闭塞患者,共230例,中位年龄71岁(IQR 60-78),47%为女性。

主要发现

  • 90例(39%)在转院前接受静脉溶栓,未溶栓主要因发病超过4.5小时(61%)或使用抗凝药(14%)。
  • 初级卒中中心中位NIHSS评分为14(IQR 7-24)。
  • 调整主要混杂因素后,静脉溶栓与3个月良好结局独立相关(39% vs 24%,aOR 2.02,95%CI 1.03-3.97,p=0.04)。
  • 静脉溶栓与转院期间基底动脉再通相关(aOR 23.7,95%CI 6.9-81.3,p<0.001)。
  • 90天死亡率(aOR 1.12,95%CI 0.58-2.18)和24小时任何脑出血(aOR 1.55,95%CI 0.77-3.1)在溶栓与非溶栓患者间无显著差异。

关键数值与推荐

  • 主要有效性结局为3个月良好功能结局(改良Rankin量表评分0-2)。
  • 次要有效性结局包括极好结局(mRS评分0-1)和转院期间基底动脉再通(到达综合卒中中心时改良脑梗死溶栓评分2a-3)。
  • 安全性结局包括3个月死亡率和24小时影像学上的任何脑出血。

临床怎么用

  • 对于从初级卒中中心转至综合卒中中心考虑取栓的基底动脉闭塞患者,转院前静脉溶栓可能改善再通和功能结局且不增加安全风险。
  • 当前仅39%的患者接受转院前静脉溶栓,提示需重新评估该场景下静脉溶栓的纳入标准。

局限性

  • 样本量有限且为观察性设计,研究结果需未来研究证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The benefit of IV thrombolysis (IVT) before endovascular therapy (EVT) in acute ischemic stroke patients with basilar artery occlusion (BAO) remains unclear. Most existing studies have focused on patients directly admitted to comprehensive stroke centers (CSCs), where EVT is readily available. Our objective was to evaluate the effectiveness and safety of IVT initiated before interhospital transfer in patients with BAO initially admitted to a primary stroke center (PSC). METHODS: We analyzed data from 3 prospectively collected cohorts of patients with BAO transferred from a PSC to a CSC (Rothschild Foundation Hospital, Montpellier University Hospital, Stanford Hospital) for EVT consideration, regardless of whether EVT was ultimately performed. The primary effectiveness outcome was favorable 3-month functional outcome (modified Rankin Scale [mRS] score 0-2). Secondary effectiveness outcomes included excellent outcome (mRS score 0-1) and basilar artery recanalization during transfer (modified Thrombolysis In Cerebral Infarction score 2a-3 at CSC arrival). Safety outcomes included 3-month mortality and any intracerebral hemorrhage (ICH) on 24-hour imaging. The relationship between outcomes and IVT was assessed using multivariable logistic regression adjusting for relevant confounders. RESULTS: A total of 230 patients were included (median age, 71 years [interquartile range (IQR) 60-78]; 47% female). Ninety (39%) received IVT before transfer. IVT was mostly withheld because of presentation beyond 4.5 hours (61%) or anticoagulant use (14%). The median NIHSS score at the PSC was 14 (IQR 7-24). In multivariable analyses adjusted for the main confounders, IVT was independently associated with favorable 3-month outcome (39% vs 24%, adjusted odds ratio [aOR] 2.02, 95% CI 1.03-3.97, p = 0.04). Regarding secondary outcomes, IVT was associated with basilar recanalization during transfer (aOR 23.7, 95% CI 6.9-81.3, p < 0.001) while mortality at 90 days (aOR 1.12, 95% CI 0.58-2.18) and any ICH at 24 hours (aOR 1.55, 95% CI 0.77-3.1) did not significantly differ between IVT-treated and non-IVT-treated patients. DISCUSSION: In patients with BAO transferred for thrombectomy consideration, IVT before transfer was associated with improved recanalization and functional outcomes, without significant safety concerns. However, IVT was administered in only 39% of patients, suggesting a potential need to broaden IVT eligibility criteria in this setting. These findings require confirmation in future studies, given the limited sample size and observational design. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that in patients with BAO, administering IVT before hospital transfer for thrombectomy is safe and associated with a favorable functional outcome at 3 months.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Liebart S, Lansberg MG, Adwane G, et al. Effectiveness and Safety of IV Thrombolysis Before Hospital Transfer for Thrombectomy in Patients With Basilar Artery Occlusion. Neurology. 2025. PMID: 41259723. doi:10.1212/WNL.0000000000214355

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。